The metabotropic glutamate receptors: Potential drug targets for the treatment of anxiety disorders?

European Journal of Pharmacology

Volumn 723, Issue 1, 2014, Pages 181-184

  Pitsikas, Nikolaos ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Anxiety; Metabotropic glutamate receptors

Indexed keywords

1 AMINO 1,5 INDANDICARBOXYLIC ACID; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; ANXIOLYTIC AGENT; EGLUMETAD; FENOBAM; JNJ 16259685; LY 314582; LY 456236; LY 566332; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; MSG 0039; PLACEBO; TALAGLUMETAD; UNCLASSIFIED DRUG;

ANXIETY DISORDER; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TRANQUILIZING ACTIVITY;

ANXIETY; METABOTROPIC GLUTAMATE RECEPTORS;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; GLUTAMIC ACID; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84893798736     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.12.019     Document Type: Article

References (42)

1. G. Battaglia, V. Bruno, V. Pisani, D. Centoze, M. Vincenza, P. Calabresi, and F. Nicoletti Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission Mol. Cell. Neurosci. 17 2001 1071 1083 (Pubitemid 32641875)
2. V. Bergink, and H.G.M. Westernberger Metabotropic glutamate II receptors in panic disorder: a double blind clinical trial with LY354740 Int. Clin. Psychopharmacol. 20 2005 291 293 (Pubitemid 41475316)
3. A.Y. Bespalov, M.M. van Gaalen, I.A. Sukhotina, K. Wicke, M. Mezler, H. Schoemaker, and G. Gross Behavioral characterization of the mGlu group II/III receptor antagonist LY-341495, in animal models of anxiety and depression Eur. J. Pharmacol. 592 2008 96 102
4. C.S. Busse, J. Brodkin, D. Tattersall, J.J. Anderson, N. Warren, and L. Tehrani et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety Neuropsychopharmacology 29 2004 1971 1979 (Pubitemid 39486548)
5. L.E. Chavez-Noriega, H. Schaffhauser, and U.C. Campbell Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia Curr. Drug Targets CNS Neurol. Disord. 1 2002 261 281
6. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37 1997 205 237 (Pubitemid 27238875)
7. J.F. Cryan, and F.F. Sweeney The age of anxiety: role of animal models of anxiolytic action in drug discovery Br. J. Pharmacol. 164 2011 1129 1161
8. E. Dunayevich, J. Erickson, L. Levine, R. Landbloom, D.D. Schoepp, and G.D. Toellefson Efficacy and tolerability of an mGlu2/3 receptor agonist in the treatment of generalized anxiety disorder Neuropsychopharmacology 33 2008 1603 1610 (Pubitemid 351684700)
9. M.E. Goldberg, A.I. Salama, J.B. Patel, and J.B. Malick Novel non-benzodiazepine anxiolytics Neuropharmacology 22 1983 1499 1504 (Pubitemid 14175498)
10. J.M. Gorman New molecule targets for antianxiety interventions J. Clin. Psychiatry 64 2003 28 35 (Pubitemid 36389869)
11. C. Grillon, J. Cordova, L.R. Levine, and C.A. Morgan III Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans Psychopharmacology 168 2003 446 454 (Pubitemid 36994028)
12. V. Grivas, A. Markou, and N. Pitsikas The metabotropic glutamate 2/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety Eur. J. Pharmacol. 715 2013 105 110
13. M.B. Hammer, S. Robert, and B.S. Fruech Treatment-resistant posttraumatic stress disorder: strategies for intervention CNS Spectr. 9 2004 740 752
14. B.H. Harvey, and M. Shahid Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models Pharmacol. Biochem. Behav. 100 2012 775 800
15. V. Heidinger, P. Manzerra, Z.Q. Wang, U. Strasser, S.P. Yu, D.W. Choi, and M.M. Behrens Metabotropic glutamate receptor 1-indiuced upregulation of the NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons J. Neurosci. 22 2002 5452 5461 (Pubitemid 35386467)
16. M. Iijima, T. Shimazaki, A. Ito, and S. Chaki Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hypothermia test in singly housed mice Psychopharmacology 190 2007 233 239 (Pubitemid 46011183)
17. G. Imre, A. Salomons, M. Jongsma, D.S. Fokkema, J.A. Den Boer, and G.J. Ter Horst Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat Pharmacol. Biochem. Behav. 84 2006 392 399 (Pubitemid 44292240)
18. W. Jacob, A. Gravius, M. Pietraszek, J. Nagel, I. Belozertseva, E. Shekunova, A. Malyshkin, S. Greco, C. Barberi, and W. Danysz The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning Neuropharmacology 57 2009 97 108
19. M. Kellner, C. Muhtz, K. Stark, A. Yassouridis, J. Arlt, and K. Wiedemann Effects of a metabotropic glutamate2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results Psychopharmacology 179 2005 310 315 (Pubitemid 40576719)
20. J.H. Krystal, S.J. Mathew, D.C. D'Souza, A. Garakani, H. Gunduz-Bruce, and D.S. Charney Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists CNS Drugs 24 2010 669 693
21. L. Levine, B. Gaydos, D. Shehhan, A. Goddard, J. Feighner, W.Z. Potter, and D.D. Schoepp The mGlu2/3 receptor agonist, LY354740 reduces panic anxiety induced bya CO2 challenge in patients diagnosed with panic disorders Neuropharmacology 43 2002 294 295
22. A.M. Linden, and D.D. Schoepp Metabotropic glutamate receptor targets for neuropsychiatric disorders Drug Discov. Today: Ther. Strateg. 3 2006 507 517 (Pubitemid 46076174)
23. A.M. Linden, S.J. Greene, M. Bergeron, and D.D. Schoepp Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions Neuropsychopharmacology 29 2004 502 513 (Pubitemid 38365926)
24. D. Michelson, L.R. Levine, M.A. Dellva, P. Mesters, D.D. Schoepp, D. Dunayevich, and G.D. Tollefson Clinical studies with mGlu2/3 agonists: LY354740 compared with placebo in patients with generalized anxiety disorder Neuropharmacology 49 2005 257
25. M.J. Millan The neurobiology of anxious states Prog. Neurobiol. 70 83 2003 244
26. J.A. Monn, M.J. Valli, S.M. Massey, M.M. Hansen, T.J. Kress, J.P. Wepsiec, A.R. Harkness, J.L. Grutsch, R.A. Wright, B.G. Johnson, S.L. Andis, A. Kingston, R. Tomlison, R. Lewis, K.R. Griffey, J.P. Tizzano, and D.D. Schoepp Synthesis, pharmacological characterization, and molecular modelling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0.] hexane-2,6-dicaboxylic acid (LY354740): identification of two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors J. Med. Chem. 42 1999 1027 1040 (Pubitemid 29153432)
27. F. Nicoletti, J. Bockaert, G.L. Collingridge, P.J. Conn, F. Ferraguti, D.D. Schoepp, J.T. Wroblewski, and J.P. Pin Metabotropic glutamate receptors: from the workbench to the bedside Neuropharmacology 60 2011 1017 1041
28. A. Palucha, and A. Pilc Metabotropic glutamate receptors ligands as possible anxiolytic and antidepressant drugs Pharmacol. Ther. 115 2007 116 147 (Pubitemid 46992810)
29. J.C. Pecknold, D.J. McClure, L. Appeltauer, L. Wrzesinski, and T.J. Allan Treatment of anxiety with fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study Clin. Psychopharmacol. 2 1982 129 133 (Pubitemid 12025672)
30. P.S. Pinheiro, and C. Mulle Presynaptic glutamate receptors: physiological functions and mechanisms of action Nat. Rev. Neurosci. 9 2008 423 436
31. R.H. Porter, G. Jaeschke, W. Spooren, T.M. Ballard, B. Buttelmann, and S. Kolczewski et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonistic activity J. Pharmcol. Exp. Ther. 315 2005 711 721 (Pubitemid 41500737)
32. A. Satow, S. Maehara, S. Ise, H. Hikichi, M. Fukushima, G. Suzuki, T. Kimura, T. Tanaka, S. Ito, H. Kawamoto, and H. Ohta Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonists in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist FTIDC [4-[1-(2-Fluoropyridine-3-yl) -5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H) -carboxamide] J. Pharmacol. Exp. Ther. 326 2008 577 586
33. D.D. Schoepp Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system J. Pharmacol. Exp. Ther. 200 2001 12 20 (Pubitemid 32905113)
34. D.D. Schoepp, and G.J. Marek Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr. Drug Targets CNS Neurol. Disord. 1 2002 215 225
35. R. Shigemoto, and N. Mizuno Metabotropic glutamate receptors - immunocytochemical and in situ hybridization analysis O.P. Ottersen, J Storm-Mathisen, Handbook of Chemical Neuroanatomy 2000 Elsevier Science Amsterdam 63 98
36. S. Shimazaki, M. Iijima, and S. Chaki Anxiolytic-like activity of MSG0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behaviour test Eur. J. Pharmacol. 501 2004 21 125
37. W. Spooren, A. Lesage, H. Lavreysen, F. Gasparini, and T. Steckler Metabotropic glutamate receptors: their therapeutic potential in anxiety Curr. Top. Behav. Neurosci. 2 2010 391 413
38. C.J. Swanson, M. Bures, M.P. Johnson, A.M. Linden, J.A. Monn, and D.D. Schoepp Metabotropic glutamate receptors as novel targets for anxiety and stress disorders Nat. Rev. Drug Discov. 4 2005 131 144 (Pubitemid 40277494)
39. M. Van Ameringen, C. Mancini, B. Pipe, and M. Bennett Optimizing treatment in social phobia: a review of treatment resistance CNS Spectr. 9 2004 753 762 (Pubitemid 39473445)
40. G.B. Varty, M. Grilli, A. Forlani, S. Freduzzi, M.E. Grzelak, D.H. Guthrie, R.A. Hodgson, S.X. Lu, E. Nicolussi, A.J. Pond, E.M. Parker, J.C. Hunter, G.A. Higgins, A. Regianni, and R. Bertorelli The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist LY456236, in rodents: a comparison of efficacy and side-effects profiles Psychopharmacology 179 2005 207 217 (Pubitemid 40576708)
41. J.M. Wieronska, and A. Pilc Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs Neurochem. Int. 55 2009 85 97
42. J.M. Wieronska, K. Stanchowicz, P. Branski, A. Patucha-Poniewiera, and A. Pilc On the mechanism of anti-hyperthermic effects of LY379268 and LY487379 group II mGlu receptor activators, in the stress-induced hypothermia in singly housed mice Neuropharmacology 62 2012 322 331